Nabriva Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Net Income	-57.19	-49.45	-69.48	-82.76	-114.78	-74.36	-54.89	-46.96	-14.22	12.33
Depreciation & Amortization	0.22	0.64	0.82	0.4	0.51	0.43	0.23	0.15	0.17	0.16
Share-Based Compensation	1.97	3.29	5.22	9.75	5.15	5.73	2.55	1.35	0.1	0.14
Other Operating Activities	18.29	-14.04	-7.89	0.73	36.39	-1.16	3.79	23.6	2.55	-16.75
Operating Cash Flow	-36.71	-59.56	-71.33	-71.89	-72.72	-69.35	-48.33	-21.86	-11.41	-4.12
Capital Expenditures	-0.21	-0.03	-0.11	-0.06	-0.23	-1.17	-0.6	-0.22	-0.09	-0.03
Acquisitions	0	0	0	0	-4.26	50.95	0	0	0	0
Change in Investments	0	0	0	0	-0.12	-0.03	23.96	-76.49	0	2.75
Other Investing Activities	-0.05	-0.06	-0.16	0.39	-	-	-	-	-	-
Investing Cash Flow	-0.26	-0.08	-0.27	0.33	-4.6	49.75	23.35	-76.7	-0.09	2.72
Share Issuance / Repurchase	2.12	27.91	54.17	20.51	50	80.08	0.27	106.09	0	0
Debt Issued / Paid	0.54	42.28	-22.48	37.93	47.76	0.23	24.82	40.89	8.56	1.01
Other Financing Activities	-0.81	-3.83	-4.76	-2.36	-4.84	-8.09	-2.79	-13.96	0.54	0.11
Financing Cash Flow	1.85	66.37	26.92	56.08	92.92	72.22	22.3	133.02	9.1	1.12
Exchange Rate Effect	-0.17	-0.48	-0.14	-0.11	-0.36	1.37	-1	-0.16	-0.41	0
Net Cash Flow	-35.3	6.24	-44.82	-15.59	15.23	53.99	-3.67	34.3	-2.81	-0.28
Free Cash Flow	-36.92	-59.58	-71.44	-71.95	-72.95	-70.52	-48.93	-22.07	-11.49	-4.15
Free Cash Flow Margin	-99.96%	-206.20%	-1421.21%	-758.92%	-755.51%	-1325.79%	-754.83%	-585.98%	-479.32%	-14.41%
Free Cash Flow Per Share	-1.38	-3.44	-13.90	-24.24	-35.91	-59.10	-56.95	-52.14	-884.96	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).